Samsung Biologics signs a contract manufacturing agreement of KRW 17.8 billion with U.S. pharma

Samsung Biologics announced conclusion of a contract manufacturing agreement with a U.S. pharmaceutical company on 21 February.

The agreed payment is approximately KRW 17.8 billion(6.06% of recent sales), and the start date of the agreement is 21 February.

The term of the agreement is confidential in management, and the company said it will be disclosed on 31 December 2019.

In addition, if t...